A Phase II Study of Sorafenib with Chemotherapy, Radiation, and Surgery for High-Risk Soft Tissue Sarcomas
The purpose of this study is to determine the effects, good and/or bad of the study drug, sorafenib, in combination with chemotherapy and radiation.
Soft Tissue Sarcoma
Subjects must be 18 years of age or older.
Subjects must have a diagnosis of soft tissue sarcoma of their extremity or body wall.
Have not had prior anti-cancer treatment.
Subject's medical history will be reviewed in detail for study eligibility.
Other eligibility criteria will apply
18 - 99
Healthy Volunteers Needed
Duration of Participation
Approximately 5 years.
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
Bayer HealthCare Pharmaceuticals, Inc.